High Grade Upper tract Urothelial Carcinoma (UTUC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

According to specific studies, patients with a history of upper urinary tract infections and those who have a low glomerular filtration rate (eGFR) have a higher incidence of UTUC. Urography, the first imaging modality currently used for UTUC screening, offers greater diagnostic accuracy, and many guidelines have only recently been updated to reflect this. Upper urinary tract cancer can be treated in one of two ways. Nephron prophylaxis, also known as conservative treatment, is the preservation of the kidney, either entirely or in part, while minimizing negative effects on kidney function. Using small tools and cameras that can reach the ureters and kidneys and focus only on the tumor, ablation is a technique for eliminating tumors without performing open surgery. Chemotherapy regimens that are frequently used in treating NHL are usually used to treat RS. Usually, the overall response rate of these systems is around 30%. Rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone make up the R-CHOP chemotherapy regimen, which is the usual first-line therapy.

Description

High-grade tumors can invade the kidney or ureter and have an aggressive appearance under the microscope. The detrusor, a thickened bladder muscle, serves as a barrier to contain invasive cancers, but the kidneys and ureters don't have this muscle. Radical nephrectomy, a surgical removal of the kidneys and ureters, is typically used to treat high-grade UTUC, which can spread through the kidneys or ureters. High-grade UTUC can be aggressive, so doctors may advise systemic therapy (like chemotherapy) before or after surgery to lower the risk of recurrence elsewhere in the body. Cancer of the lining of the urinary tract is referred to as urothelial carcinoma. Upper urinary tract cancer (UTUC) refers to a subset of urothelial cancers that originate in the kidney (referred to as the renal pelvis) or the lining of the ureter, despite the fact that the majority of urothelial cancers (roughly 90-95%) do so in the bladder. a lengthy, skinny tube that joins the kidney and bladder). There are many similarities and some differences between UTUC and bladder cancer because the lining of the bladder, kidneys, and ureters is the same. For instance, hematuria (blood in the urine) can be linked to both UTUC and bladder cancer. To the contrary, UTUC can obstruct the ureters or kidneys, resulting in swelling (medically referred to as hydronephrosis) and inflammation, and in some cases even affecting kidney function. The renal pelvis and ureter are only rarely affected by UTUC. Radical nephrectomy is the typical treatment for high-grade disease, with 5-year cancer-specific survival rates for pT3 disease, pT4 disease, and pN disease being less than 50%, 5%, and 35%, respectively, for each.

High Grade Upper tract Urothelial Carcinoma (UTUC) (Epidemiology)

According to specific studies, patients with a history of upper urinary tract infections and those who have low glomerular filtration rates (eGFR) have a higher incidence of UTUC. One study suggests that UTUC is the most prevalent of the uncommon urogenital cancers, but the incidence of UTUC has been reported in other studies as well. Furthermore, only one study-which was restricted to information from the Swedish Cancer Registry-reported the incidence of UTUC among Lynch syndrome patients and included data spanning 40 years. The use of urinary computed tomography (CT) to detect UTUC over time may be connected to the overall increase in the incidence of UTUC reported in some studies. A new diagnostic option for UTUC, computed tomography (CT) urography has long dominated intravenous urography. Given that urography is currently the first imaging modality used for UTUC screening, many guidelines have only recently been updated to take into account the higher diagnostic accuracy it offers. It has been hypothesized that increased exposure to asbestos fibers on board is to blame for the relatively high incidence of UTUC among seafarers. In order to better understand the connection between workplace exposure and the incidence of bladder cancer and other urinary tract cancers in seafarers, the Nordic Occupational Cancer Cohort Study was conducted. Bladder cancer has also been linked to an increased incidence of exposure to other chemicals, such as azo dyes used in the printing and dyeing industries. This may help to explain why printers Michalek et al. have a higher incidence of UTUC. Michalek et al. describe yet another facet of occupational exposure. The highly statistically significant clinician-adjusted SIR for smoking, which also suggests that this is due to observation, may be caused by phenacetin and X-ray/gamma-ray exposure, according to their study of smoking-adjusted rates. greater prejudice and focus on cancer symptoms by medical professionals. Uroepithelium. Blacks and whites in the US experience UTUC at varying rates, according to studies that report on overall racial values. White Americans have a higher reported SIR for renal pelvis cancer than black Americans. Studies have been done and other urinary tract cancers have been found to have racial differences between blacks and whites in the United States. It is challenging to pinpoint the origin of this disparity because it may be caused by genetics or lifestyle choices like smoking or a lack of access to healthcare. Due to the widespread consumption of aristolic acid, which has been identified as a risk factor for UTUC, studies in Taiwan have shown a comparatively high incidence of UTUC. This nephrotoxic and carcinogenic compound, which is present in herbal medicines, has been connected to an elevated risk of urinary tract cancer and was outlawed in Taiwan in 2003. Wang et al. studied the impact of aristolochic acid blockers on the incidence of UTUC. The authors state that SIR40-84 decreased in both men and women after the ban, but they also pointed out that additional research is needed on another carcinogenic and nephrotoxic substance (Xi-Xin), which is widely used in Taiwan and is similar to aristolic acid. Cancer epidemiology research frequently uses the SEER (Surveillance, Epidemiology and End Results) database, which compiles information on cancer incidence in the United States. However, SEER kidney cancer and renal pelvic cancer are categorized as renal pelvic cancer in some studies. Because renal cell carcinoma and urothelial carcinoma are histologically and tissue-specifically distinct diseases that develop in different tissues, renal cancer and renal pelvis cancer are not the same. The distinct ICD-10 codes C64 (renal metastases other than renal pelvis), C65 (renal pelvic metastases), and C66 (ureteral metastases) assigned to each type of cancer reflect this.

High Grade Upper tract Urothelial Carcinoma (UTUC) -Current Market Size & Forecast Trends

The market for high-grade upper tract urothelial carcinoma (UTUC) is expected to grow significantly, with the global urothelial carcinoma treatment market projected to reach approximately USD 2.01 billion in 2025 and continue expanding to around USD 17.9 billion by 2037, reflecting a compound annual growth rate (CAGR) of over 21.2% during the forecast period from 2025 to 2037. The increasing incidence of bladder and upper tract cancers, along with advancements in treatment options such as immunotherapy and targeted therapies, are key drivers of this growth. The rising prevalence of risk factors, including smoking and occupational exposures, further contributes to the demand for effective treatment solutions. North America is anticipated to dominate the market due to its advanced healthcare infrastructure and significant investments in cancer research and drug development. As awareness of UTUC increases and new therapies enter the market, the high-grade UTUC segment is well-positioned for robust expansion through 2035.

Upper urinary tract cancer can be treated in one of two ways. Nephron prophylaxis, also known as conservative treatment, is the preservation of the kidney, either entirely or in part, while minimizing negative effects on kidney function. Using tiny instruments and cameras that can enter the ureters and kidneys and focus only on the tumor, ablation is a technique used to remove tumors without performing open surgery. Some cancers may also benefit from pelvic or urethral immunotherapy or local chemotherapy. Robotic surgery, which allows for more precise surgery and a quicker patient recovery, may be the best choice depending on the location of the tumor to remove all or part of the ureter, kidney, and bladder. Low-grade UTUC should attempt kidney-saving surgery. High-grade disease is usually treated with radical nephrectomy combined with bladder cuff resection. After RNU, postoperative bladder chemotherapy should be administered to lower the incidence of intravesical recurrence. The grade and stage of the tumor must be taken into consideration when selecting a treatment. Similar to radical nephrectomy in terms of disease-free survival, endoscopic low-grade, noninvasive UTUC may increase the risk of intravesical recurrence. Although further proof of the therapeutic benefit is required, lymphadenectomy seems to be important for high-risk diseases. Little research has been done to support the use of BCG and mitomycin C as monotherapies and adjunctive therapies in UTUC. Adjuvant chemotherapy for T2 N0-3M0 disease should be the norm, according to a randomized clinical trial that found that platinum-based chemotherapy for invasive UTUC increased disease-free survival. In order to effectively treat bladder urothelial cancer, the medication mitomycin-C is injected into the bladder and flushed where patients are for a brief period of time before urinating. In 1963, the antibiotic mitomycin-c was first created. Even though it is a less effective antibiotic, it has developed a strong track record in the fight against cancer.

Report Highlights

High Grade Upper tract Urothelial Carcinoma (UTUC) - Current Market Trends

High Grade Upper tract Urothelial Carcinoma (UTUC) - Current & Forecasted Cases across the G8 Countries

High Grade Upper tract Urothelial Carcinoma (UTUC) - Market Opportunities and Sales Potential for Agents

High Grade Upper tract Urothelial Carcinoma (UTUC) - Patient-based Market Forecast to 2035

High Grade Upper tract Urothelial Carcinoma (UTUC) - Untapped Business Opportunities

High Grade Upper tract Urothelial Carcinoma (UTUC) - Product Positioning Vis-a-vis Competitors' Products

High Grade Upper tract Urothelial Carcinoma (UTUC) - KOLs Insight